Eiger is focused on the development and commercialization of first-in-class, well-characterized drugs for serious rare and ultra-rare diseases for patients with highly unmet medical needs.

First-In-Class Therapies of Patients In Need

(Swipe to interact)
Targeted
Indication
Drug Orphan
US / EU
Breakthrough Therapy Rare Pediatric
Disease*
Status
Hepatitis
Delta Virus
Lonafarnib
+
Ritonavir
N/A Phase 3
Peginterferon
Lambda
N/A Phase 3 Ready

Gilford Icon Bold

Progeria and
Progeroid Laminopathies

NDA / MAA Filed
PDUFA Date November 2020

Post-Bariatric Hypoglycemia

Avexitide N/A Phase 3 Ready

Congenital Hyperinsulinism

Phase 2

* Eligible for Priority Review Voucher (PRV)